The Drug Eluting Technology Show

The DET clinical program is a full educational program featuring a panel of experts, Key opinion leaders in their respective specialties, aiming at raising awareness about the use of drug-eluting technologies, which have emerged as effective and safe options for treating PAD, especially when compared to POBA or bare metal stents.

• Share your experience your peers by submitting your clinical case featuring any DET solution in treating one your patient PAD to help growth the knowledge in the scientific community.
• By submitting your clinical case, you have the opportunity to be chosen by the program jury from a select group of expert cases. These cases will be presented to a broader community of practitioners who can engage with and learn from you during a live case procedure event, which will be broadcast on February 14th. Learn more>>>
• Enhance your skills by joining the live case procedure planned to be broadcasted from a center located in the United kingdoms with a stellar panel of experts commenting the case. Learn more about how to deal with complex lesions as well as how to effectively manage long lesions vs other lesions.

Don’t miss this opportunity. This program is CME accredited.

Register now if you are not an Incathlab member yet

Program Agenda :

Part 1
Drug eluting Technology : Where we stand now

1. Paclitaxel Safety

• Overview of recent findings on the safety profile of paclitaxel.
• Discussion of the FDA's updated stance on paclitaxel-coated devices post-2018 mortality signal.
• Examination of the latest meta-analysis and its implications for clinical practice.

2. DES & DCB Benefits Over BMS and POBA

• Comparison of drug-eluting stents (DES) and drug-coated balloons (DCB) with bare-metal stents (BMS) and plain old balloon angioplasty (POBA).
• Analysis of long-term outcomes, including restenosis rates and reintervention needs.
• Review of clinical studies supporting the efficacy of DES and DCB.

3. Paclitaxel vs. Limus

• Comparison of paclitaxel-based therapies with limus-based therapies in vascular interventions.
• Discussion on mechanisms of action, efficacy, and safety profiles.
• Review of clinical evidence supporting the use of each drug class.

4. The Restenosis Challenge

• Overview of the mechanisms leading to restenosis after vascular interventions.
• Current strategies to mitigate restenosis, including advancements in medical device technology.
• Case studies highlighting successful management of restenosis.

5. Dealing with Complex Cases: DES Vs DCB optimal strategy?

• Strategies for managing patients with complex vascular conditions.
• Discussion on multidisciplinary approaches and individualized treatment plans.

Part 2
Livecase procedure from UK

Part 3
Sharing experiences and best practices: DET Clinical Cases collected review and discussion

• Clinical Case #1
• Clinical Case #2
• Clinical Case #3
• Clinical Case #4